SynthesisHead and neck pathology2025
Association of Epithelial to Mesenchymal transition Markers on Prognosis and Clinicopathological Characteristics in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinicopathological Significance of Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
- Exploratory Expression Analysis of Stem Cell and Epithelial-Mesenchymal Transition Markers in Ameloblastoma.International journal of molecular sciences · 2026Article
- Keratin 1 and keratin 18 as immunohistochemical markers for distinguishing pulmonary metastases of oral squamous cell carcinoma from primary lung squamous cell carcinoma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC) is the most common oral malignancy, often associated with poor outcomes due to metastasis and late detection. The epithelial-to-mesenchymal transition (EMT) is central to OSCC progression, but the prognostic role of EMT markers remains unclear. This systematic review and meta-analysis evaluated five key EMT markers-E-cadherin, EpCAM, Vimentin, TWIST, and SNAIL-in OSCC.
methodsFollowing PRISMA guidelines, studies were retrieved from PubMed, Scopus, Embase, ClinicalTrials.gov, and Google Scholar up to May 2025. Pooled odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) were calculated using RevMan 5.4.1 Heterogeneity was assessed by the I2 index, and fixed- or random-effects models were applied.
resultsSeventy-three observational studies were included. Vimentin showed the strongest prognostic effect, being significantly associated with lymph node metastasis (OR = 11.84, 95% CI 7.56-18.53, p < 0.00001), advanced TNM stage (OR = 6.88, p < 0.00001), poor differentiation (OR = 7.37, p < 0.00001), and poor overall survival (HR = 5.09, p < 0.00001). TWIST (HR = 4.96, p < 0.00001) and SNAIL (HR = 2.06, p = 0.0003) were also strongly predictive of aggressive clinicopathological features and worse survival. Loss of E-cadherin correlated with poor differentiation (OR = 2.80, p < 0.00001) and reduced disease-free survival (RR = 0.80, p = 0.0005), though its effect on overall survival was inconsistent. EpCAM expression showed context-dependent roles, with high expression linked to advanced stage and poor OS, whereas low expression predicted poor differentiation. Overall, Vimentin and TWIST consistently emerged as the strongest predictors of adverse outcomes, while preserved E-cadherin was protective.
conclusionVimentin, TWIST, and SNAIL are strong predictors of aggressive disease and poor survival in OSCC, while preserved E-cadherin is protective. EMT markers hold promise for prognostic assessment and precision management in OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.